ADC Summit - Practical Recommendations in Immuno and Molecular Oncology (PRIMO)

Registration Information

Registration is now open

PRIMO ADC Summit
January 27, February 3, February 17, 2021

Registration is FREE for all Healthcare Practitioners

Objectives

Review this comprehensive program, including an on-demand Webcast and downloadable slidesets to gain expert perspectives on the emerging clinical data of ADCs and participate in discussion regarding:

  • The structure of ADCs and how they are unique in cancer therapy
  • Review of emerging clinical data with ADCs, including recent ongoing clinical trials, mechanism of action, and current and future treatment options
  • Integration of ADCs in the management of solid tumors and in treatment sequencing
  • Practical considerations for the use of ADCs, including the management of adverse events

Target Audience

This activity has been designed to meet the educational needs of Academic and Community Practitioners, as well as Registered Nurses and Advanced Practice Registered Nurses, Pharmacists and Physician Assistants involved in the care of patients with breast, lung, and gastrointestinal cancers.

On-Demand Webcasts

Session Title:

The Emerging Role of Antibody–Drug Conjugates (ADCs) in Breast Cancer

Learning Objectives:

Review 3 FDA-approved ADCs and ADCs in clinical development for breast cancer

  • Analyze the unmet need in patients with breast cancer
  • Discuss their mechanism of action
  • Analyze available clinical data and discuss ongoing clinical trials

Slides are available to download here.

Click here to view the session agenda for: The Emerging Role of Antibody–Drug Conjugates (ADCs) in Breast Cancer
TIME
TOPICS
SPEAKERS
0:00:00
Welcome and Objectives
Agarwala
0:03:26
Introduction to ADCs
  • Where do we stand and where are we going?
 
  • Daver
0:21:38 – 0:42:41
  • 0:21:38
  • 0:26:26
  • 0:35:30
  • 0:42:41
ADCs in Breast Cancer
  • FDA-Approved ADCs in Breast Cancer
  • ADCs Targeting HER2
  • T-Dxd in HER2-Low
  • ADCs in Triple Negative Breast Cancer
 
  • Hurvitz
  • Gradishar
  • Hurvitz
  • Gradishar
0:55:00
Updates from SABCS
Hurvitz
1:10:14 – 1:14:52
Treatment considerations for ADCs in Breast Cancer
  • Clinical Applications of ADCs
  • Combinations with Immunotherapy
 
  • Hurvitz
  • Gradishar
1:19:57
Q & A
Hurvitz + Daver
Session Title:

Clinical Applications of ADCs

Learning Objectives:

Identify current thinking and rationale around patient selection and sequencing of ADCs in breast cancer

Slides are available to download here.

Click here to view the session agenda for: Clinical Applications of ADCs
TIME
TOPICS
SPEAKERS
0:00:00
Welcome and Objectives
Agarwala
0:03:22
Introduction to ADCs
  • Where do we stand and where are we going?
 
  • Daver
0:20:40 – 1:13:20
  • 0:21:30
  • 0:25:40
  • 0:48:38
  • 1:00:14
Practical Considerations of ADC’s
  • ADCs in Triple Negative Breast Cancer
  • Patient Case #1
  • ADCs in HER2+ Breast Cancer
  • Patient Case #2 & #3
 
  • Hurvitz
  • Hurvitz + Gradishar
  • Gradishar
  • Hurvitz + Gradishar
1:13:20
Live Q/A
Hurvitz + Gradishar
Session Title:

The Emerging Role of ADCs in Lung, Gastric, and Colorectal Cancers

Learning Objectives:

Review ADCs in development for Non-small Cell Lung Cancer (NSCLC), Gastric cancers, and Colorectal Cancer (CRC)

  • Analyze the unmet need in patients with these NSCLC, Gastric cancers, and CRC
  • Discuss their mechanisms of action
  • Analyze available clinical data and discuss ongoing clinical trials

Slides are available to download here.

Click here to view the session agenda for: The Emerging Role of ADCs in Lung, Gastric, and Colorectal Cancers
TIME
TOPICS
SPEAKERS
0:00:00
Welcome and Objectives
Agarwala
0:03:30
Introduction to ADCs
  • Where do we stand and where are we going?
 
  • Daver
0:20:27 – 00:50:00
  • 0:21:22
  • 0:36:28
ADCs in NSCLC with updates from WCLC
  • Trastuzumab Deruxtecan, SAR408701
  • Sacituzumab Govitecan, Patritumab Deruxtecan, Telisotuzumab Vedotin
 
  • West
  • Ramalingam
00:50:00
ADCs in Gastrointestinal Cancers with updates from ASCO GI
Shroff
1:13:07
Live Q/A
West, Ramalingam (Lung); Shroff (GI/CRC)

Faculty Info

Naval G. Daver, MD

Houston, TX

  • Associate Professor
    Department of Leukemia
    MD Anderson Cancer Center

William J. Gradishar, MD, FASCO, FACP

Chicago, IL

  • Betsy Bramsen Professor of Breast Oncology
    & Professor of Medicine Chief, Division of Hematology/Oncology
  • Director, Maggie Daley Center for Women’s Cancer Care
  • Deputy Director, Clinical Network Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine

Sara A. Hurvitz, MD, FACP

Los Angeles, CA

  • Professor of Medicine
  • Director, Breast Cancer Clinical Trials Program, Division of Hematology-Oncology
    David Geffen School of Medicine, UCLA
  • Medical Director, Clinical Research Unit, Jonsson Comprehensive Cancer Center
Suresh Ramalingam, MD

Suresh Ramalingam, MD

Atlanta, GA

  • Professor of Hematology and Medical Oncology
    Roberto C. Goizueta Chair for Cancer Research
  • Director, Division of Medical Oncology
  • Deputy Director, Winship Cancer Institute
    Emory University School of Medicine
  •  
Rachna T. Shroff, MD, MS

Rachna Shroff, MD, MS

Tucson, AZ

  • Chief, Section of GI Medical Oncology
  • Director, UACC Clinical Trials Office
  • Interim Director, Arizona Clinical Trials Network
  • Vice Chair for Clinical Research, Dept of Medicine
  • Associate Professor of Medicine
    Division of Hematology/Oncology
    University of Arizona Cancer Center (UACC)
  •  
H. Jack West, MD

H. Jack West, MD

Duarte, CA

  • Associate Clinical Professor in Medical Oncology
  • Executive Director, Employer Services
    City of Hope Comprehensive Cancer Center

This activity was supported by educational grants provided by Daiichi Sankyo and Cancer Expert Now, LLC.

X

Join Cancer Expert Now's Oncology Collaboration Network

Cancer Expert Now’s service connects oncologists from around the world with distinguished leaders, generally within a few hours, to discuss disease challenges, recent literature, global clinical findings, and clinical experience in the context of specific patient cases.

Getting started is quick and easy.

Want more information?
Please contact: info@cancerexpertnow.com